Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• Males 18 years old and above
• Diagnosed with erectile dysfunction or hypogonadism
Locations
United States
California
UCI Urology | Men's Health Center
RECRUITING
Newport Beach
Contact Information
Primary
Muhammed AM Hammad, MBBCh
mahammad@hs.uci.edu
714-456-7005
Backup
Elia Abou Chawareb, MD
eaboucha@hotmail.com
714-456-7005
Time Frame
Start Date: 2025-08-13
Estimated Completion Date: 2027-01
Participants
Target number of participants: 120
Treatments
Active_comparator: PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED)
Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
Active_comparator: Testosterone Therapy in Hypogonadal Men
Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
No_intervention: Vasculogenic ED confirmed by penile Doppler ultrasound
Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: None Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
Related Therapeutic Areas
Sponsors
Leads: University of California, Irvine